Regulus Therapeutics Income Statement

Financials in millions USD. Fiscal year is July - June.

Millions USD. Fiscal year is Jul - Jun.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '24 Dec 31, 2024	Jun '24 Jun 30, 2024	Jun '23 Jun 30, 2023	Jun '22 Jun 30, 2022	Jun '21 Jun 30, 2021
Revenue	48.97	48.52	28.23	16.16	12.85
Revenue Growth (YoY)	15.04%	71.88%	74.72%	25.76%	-
Cost of Revenue	46.94	45.77	26.17	15.51	12.24
Gross Profit	2.03	2.75	2.06	0.65	0.61
Selling, General & Admin	1.14	0.95	0.81	0.28	0.21
Research & Development	0.12	0.08	0.06	0.1	0.06
Operating Expenses	1.26	1.03	0.87	0.38	0.28
Operating Income	0.77	1.72	1.2	0.27	0.33
Interest Expense	-0.05	-0.04	-0.02	-0.01	-0
Interest & Investment Income	0.21	0.08	-	-	-
Other Non Operating Income (Expenses)	0	-0.02	0.02	0	-0
Pretax Income	0.94	1.74	1.19	0.26	0.33
Income Tax Expense	0.64	0.44	0.22	0.02	0.02
Net Income	0.3	1.29	0.97	0.24	0.3
Net Income to Common	0.3	1.29	0.97	0.24	0.3
Net Income Growth	-76.70%	33.20%	296.49%	-19.56%	-
Shares Outstanding (Basic)	2	1	1	1	1
Shares Outstanding (Diluted)	2	1	1	1	1
Shares Change (YoY)	29.93%	10.82%	10.45%	-	-
EPS (Basic)	0.19	1.06	0.88	0.24	0.30
EPS (Diluted)	0.19	1.06	0.88	0.24	0.30
EPS Growth	-81.93%	20.20%	258.96%	-19.56%	-
Free Cash Flow	-3.34	-0.8	-0.92	-0.68	2.65
Free Cash Flow Per Share	-2.17	-0.66	-0.83	-0.68	2.65
Gross Margin	4.14%	5.67%	7.31%	4.01%	4.71%
Operating Margin	1.57%	3.54%	4.24%	1.66%	2.57%
Profit Margin	0.61%	2.66%	3.44%	1.51%	2.37%
Free Cash Flow Margin	-6.83%	-1.65%	-3.25%	-4.23%	20.59%
EBITDA	0.78	1.73	1.2	0.27	0.33
EBITDA Margin	1.59%	3.56%	4.27%	1.68%	2.58%
D&A For EBITDA	0.01	0.01	0.01	0	0
EBIT	0.77	1.72	1.2	0.27	0.33
EBIT Margin	1.57%	3.54%	4.24%	1.66%	2.57%
Effective Tax Rate	68.10%	25.56%	18.54%	5.78%	6.52%

Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q